Overdosage can cause severe hypertension.
Methoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a longer half-life than erythropoietin. ESA is used to increase synthesis of red blood cells to treat chronic kidney disease associated anemia.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Cyclophosphamide | The risk or severity of pulmonary toxicity can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cyclophosphamide. |
| Pegfilgrastim | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegfilgrastim. |
| Peginterferon alfa-2b | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Peginterferon alfa-2b. |
| Pegademase | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegademase. |
| Pegvisomant | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegvisomant. |
| Propylene glycol | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Propylene glycol. |
| Heptaethylene glycol | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Heptaethylene glycol. |
| Pegaptanib | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegaptanib. |
| Egaptivon pegol | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Egaptivon pegol. |
| PEG-uricase | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with PEG-uricase. |
| Peginterferon alfacon-1 | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Peginterferon alfacon-1. |
| GlycoPEG-GCSF | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with GlycoPEG-GCSF. |
| Pegnivacogin | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegnivacogin. |
| Pegpleranib | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegpleranib. |
| Pegsunercept | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegsunercept. |
| Polidocanol | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Polidocanol. |
| Peginesatide | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Peginesatide. |
| Certolizumab pegol | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Certolizumab pegol. |
| Peginterferon beta-1a | The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta. |
| Pegloticase | The therapeutic efficacy of Pegloticase can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta. |
| Polyethylene glycol | The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta. |
| Antihemophilic factor (recombinant), PEGylated | The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta. |
| Insulin peglispro | The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta. |
| Eptacog alfa pegol (activated) | The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta. |
| Olaptesed Pegol | The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta. |
| Abicipar Pegol | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta. |
| Lexaptepid pegol | The therapeutic efficacy of Lexaptepid pegol can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta. |
| Cepeginterferon alfa-2B | The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta. |
| Pegvaliase | The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta. |
| Pegamotecan | The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta. |
| Lipegfilgrastim | The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta. |
| Nonacog beta pegol | The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta. |
| Damoctocog alfa pegol | The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta. |
| Elapegademase | The therapeutic efficacy of Elapegademase can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta. |
| Nandrolone phenpropionate | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be increased when used in combination with Nandrolone phenpropionate. |
| Nandrolone decanoate | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be increased when used in combination with Nandrolone decanoate. |
| Nandrolone | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be increased when used in combination with Nandrolone. |
| Vindesine | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vindesine. |
| Vinorelbine | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vinorelbine. |
| Vincristine | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vincristine. |
| Vinblastine | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vinblastine. |
| Vintafolide | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vintafolide. |
| Vinflunine | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vinflunine. |
| Vincamine | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Vincamine. |
| Lenalidomide | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lenalidomide. |
| Thalidomide | The risk or severity of thromboembolism can be increased when Thalidomide is combined with Methoxy polyethylene glycol-epoetin beta. |
| Pomalidomide | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pomalidomide. |
| Peginterferon alfa-2a | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Peginterferon alfa-2a. |
| Pegaspargase | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pegaspargase. |
| Cetuximab | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cetuximab. |
| Denileukin diftitox | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Denileukin diftitox. |
| Leuprolide | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Leuprolide. |
| Goserelin | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Goserelin. |
| Asparaginase Escherichia coli | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Asparaginase Escherichia coli. |
| Aldesleukin | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Aldesleukin. |
| Gemtuzumab ozogamicin | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gemtuzumab ozogamicin. |
| Trastuzumab | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trastuzumab. |
| Rituximab | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rituximab. |
| Tositumomab | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tositumomab. |
| Alemtuzumab | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Alemtuzumab. |
| Octreotide | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Octreotide. |
| Interferon alfa-2b | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Interferon alfa-2b. |
| Bevacizumab | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bevacizumab. |
| Masoprocol | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Masoprocol. |
| Bortezomib | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bortezomib. |
| Pipobroman | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pipobroman. |
| Cladribine | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cladribine. |
| Cabergoline | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cabergoline. |
| Anagrelide | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Anagrelide. |
| Carmustine | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Carmustine. |
| Chlorotrianisene | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Chlorotrianisene. |
| Amsacrine | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Amsacrine. |
| Pamidronic acid | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pamidronic acid. |
| Bleomycin | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bleomycin. |
| Chlorambucil | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Chlorambucil. |
| Raltitrexed | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Raltitrexed. |
| Mitomycin | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Mitomycin. |
| Bexarotene | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bexarotene. |
| Valproic acid | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Valproic acid. |
| Gefitinib | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gefitinib. |
| Floxuridine | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Floxuridine. |
| Megestrol acetate | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Megestrol acetate. |
| Tioguanine | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tioguanine. |
| Aminoglutethimide | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Aminoglutethimide. |
| Valrubicin | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Valrubicin. |
| Sorafenib | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Sorafenib. |
| Streptozocin | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Streptozocin. |
| Trifluridine | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trifluridine. |
| Gemcitabine | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gemcitabine. |
| Teniposide | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Teniposide. |
| Epirubicin | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Epirubicin. |
| Altretamine | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Altretamine. |
| Flutamide | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Flutamide. |
| Cisplatin | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cisplatin. |
| Alitretinoin | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Alitretinoin. |
| Oxaliplatin | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Oxaliplatin. |
| Erlotinib | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Erlotinib. |
| Toremifene | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Toremifene. |
| Fluorouracil | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fluorouracil. |
| Pentostatin | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pentostatin. |